Journal: Methods and Protocols

Article Title: SARS-CoV-2 Multi-Antigen Serology Assay

doi: 10.3390/mps4040072

Figure Lengend Snippet: SARS-CoV-2 and control proteins used.

Article Snippet: IVA Switzerland H3N2-2013 , Hemagglutinin , HEK293 , Sino Biological, Beijing, China , 40497-V08H1 , Influenza A HA1, AA 1-345.

Techniques: Expressing, Recombinant, Binding Assay

Journal: Acta Naturae

Article Title: Broadly Reactive Nanobody Targeting the H3 Hemagglutinin of the Influenza A Virus

doi: 10.32607/actanaturae.27374

Figure Lengend Snippet: The recombinant HA proteins used in in vitro studies

Article Snippet: , H3 Swiz , HA0 A/Switzerland/9715293/2013 (H3N2) , Sino Biological , 40497-VNAB , EPI541659.

Techniques: Recombinant, In Vitro

Journal: Acta Naturae

Article Title: Broadly Reactive Nanobody Targeting the H3 Hemagglutinin of the Influenza A Virus

doi: 10.32607/actanaturae.27374

Figure Lengend Snippet: Production of VHH-Fc fusion proteins and their characterization in vitro : ( A ) – SDSPAGE of purified VHH-Fc under non-reducing ( 2 – 4 ) and under reducing ( 5 – 7 ) conditions: molecular weight ladder ( 1 ), D9.2-Fc ( 2, 5 ), E12.2-Fc ( 3, 6 ), and D4.2-Fc ( 4, 7 ); ( B ) – binding characteristics of VHH-Fc in relation to different Group 2 HA proteins, expressed as EC 50 (nM) based on the ELISA assay results; ( C ) – Western blot analysis of the antibody specificity of D9.2-Fc ( 1 , 2 ), D4.2-Fc ( 3, 4 ), and E12.2-Fc ( 5, 6 ) to H3 Swiz HA0 under reducing ( 1, 3, 5 ) and non-reducing ( 2, 4, 6 ) conditions; ( D ) – Western blot analysis of VHH-Fc specificity to HA1 and the HS2 subunit of the HA protein: inactivated A/Aichi/2/1968 IAV under reducing conditions, detected using D9.2-Fc ( 1 ), D4.2-Fc ( 2 ), and E12.2-Fc ( 3 ); ( E ) – ELISA demonstrating binding of VHH-Fc to H3 Aichi HA0 cleaved by trypsin-TPCK and incubated in buffer solutions with different pH and DTT; ( F ) – competitive ELISA for identification of VHH-Fc epitopes

Article Snippet: , H3 Swiz , HA0 A/Switzerland/9715293/2013 (H3N2) , Sino Biological , 40497-VNAB , EPI541659.

Techniques: In Vitro, Purification, Molecular Weight, Binding Assay, Enzyme-linked Immunosorbent Assay, Western Blot, Incubation, Competitive ELISA

Journal: Clinical and Experimental Immunology

Article Title: Differences in nasal immunoglobulin A responses to influenza vaccine strains after live attenuated influenza vaccine (LAIV) immunization in children

doi: 10.1111/cei.13395

Figure Lengend Snippet: Nasal swab IgA responses to vaccination

Article Snippet: To detect antigen‐specific responses, Nunc MaxiSorp 96‐well plates (Thermo Fisher Scientific, Loughborough, UK) were coated with 1 μg/ml recombinant haemagglutinin from H1N1 (A/California/09), H3N2 (A/Switzerland/9715293/2013), B/Phuket/3073/2013 and B/Brisbane/60/2008 antigens (Sino Biologicals, Beijing, China) and incubated overnight at 4°C.

Techniques:

Journal: Clinical and Experimental Immunology

Article Title: Differences in nasal immunoglobulin A responses to influenza vaccine strains after live attenuated influenza vaccine (LAIV) immunization in children

doi: 10.1111/cei.13395

Figure Lengend Snippet: Relationship between baseline nasal immunoglobulin (Ig)A titre and fold change in nasal IgA response. Nasal IgA titre at baseline was compared to the fold change in response to H1N1 (a), H3N2 (b), B/Bris (c) and B/Phu (d) antigens.

Article Snippet: To detect antigen‐specific responses, Nunc MaxiSorp 96‐well plates (Thermo Fisher Scientific, Loughborough, UK) were coated with 1 μg/ml recombinant haemagglutinin from H1N1 (A/California/09), H3N2 (A/Switzerland/9715293/2013), B/Phuket/3073/2013 and B/Brisbane/60/2008 antigens (Sino Biologicals, Beijing, China) and incubated overnight at 4°C.

Techniques:

Journal: Clinical and Experimental Immunology

Article Title: Differences in nasal immunoglobulin A responses to influenza vaccine strains after live attenuated influenza vaccine (LAIV) immunization in children

doi: 10.1111/cei.13395

Figure Lengend Snippet: Relationship between age and baseline nasal immunoglobulin (Ig)A. Age was compared to the nasal IgA titre at baseline to H1N1 (a), H3N2 (b), B/Bris (c) and B/Phu (d) antigens for all children.

Article Snippet: To detect antigen‐specific responses, Nunc MaxiSorp 96‐well plates (Thermo Fisher Scientific, Loughborough, UK) were coated with 1 μg/ml recombinant haemagglutinin from H1N1 (A/California/09), H3N2 (A/Switzerland/9715293/2013), B/Phuket/3073/2013 and B/Brisbane/60/2008 antigens (Sino Biologicals, Beijing, China) and incubated overnight at 4°C.

Techniques:

Journal: Clinical and Experimental Immunology

Article Title: Differences in nasal immunoglobulin A responses to influenza vaccine strains after live attenuated influenza vaccine (LAIV) immunization in children

doi: 10.1111/cei.13395

Figure Lengend Snippet: Relationship between baseline nasal immunoglobulin (Ig)A and fold change in haemagglutination inhibition assay (HAI) response. Nasal IgA titre at baseline was compared to the fold change in HAI response to H1N1 (a), H3N2 (b), B/Bris (c) and B/Phu (d) antigens.

Article Snippet: To detect antigen‐specific responses, Nunc MaxiSorp 96‐well plates (Thermo Fisher Scientific, Loughborough, UK) were coated with 1 μg/ml recombinant haemagglutinin from H1N1 (A/California/09), H3N2 (A/Switzerland/9715293/2013), B/Phuket/3073/2013 and B/Brisbane/60/2008 antigens (Sino Biologicals, Beijing, China) and incubated overnight at 4°C.

Techniques: HAI Assay

Journal: Acta Orthopaedica

Article Title: Reduction of blood loss in primary hip arthroplasty with tranexamic acid or fibrin spray

doi: 10.3109/17453674.2011.623568

Figure Lengend Snippet: Patient data

Article Snippet: Patients were randomized to 1 of 3 treatment groups: (1) tranexamic acid (Cyklokapron; Meda Pharmaceuticals, UK), (2) fibrin spray (Quixil; Omrix Biopharmaceuticals, Belgium), or (3) neither (control).

Techniques: Control